491 related articles for article (PubMed ID: 33934848)
1. Uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract][Full Text] [Related]
2. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract][Full Text] [Related]
3. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.
Sagae S; Susumu N; Viswanathan AN; Aoki D; Backes FJ; Provencher DM; Vaughan M; Creutzberg CL; Kurzeder C; Kristensen G; Lee C; Kurtz JE; Glasspool RM; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S83-9. PubMed ID: 25341586
[TBL] [Abstract][Full Text] [Related]
4. Uterine papillary serous carcinoma: state of the state.
Naumann RW
Curr Oncol Rep; 2008 Nov; 10(6):505-11. PubMed ID: 18928665
[TBL] [Abstract][Full Text] [Related]
5. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
6. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
7. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
8. Factors prognostic of survival in advanced-stage uterine serous carcinoma.
Holman LL; Pal N; Iglesias DA; Soliman PT; Balakrishnan N; Klopp A; Broaddus RR; Fleming ND; Munsell MF; Lu KH; Westin SN
Gynecol Oncol; 2017 Jul; 146(1):27-33. PubMed ID: 28465008
[TBL] [Abstract][Full Text] [Related]
9. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
10. Uterine papillary serous cancer: a review of the literature.
del Carmen MG; Birrer M; Schorge JO
Gynecol Oncol; 2012 Dec; 127(3):651-61. PubMed ID: 23000148
[TBL] [Abstract][Full Text] [Related]
11. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
12. HER2 in uterine serous carcinoma: Current state and clinical perspectives.
Navarro Sanchez JM; Finkelman BS; Turner BM; Katerji H; Wang X; Varghese S; Wang T; Peng Y; Hicks DG; Zhang H
Am J Clin Pathol; 2023 Oct; 160(4):341-351. PubMed ID: 37267036
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations in uterine serous carcinoma.
Hayes MP; Ellenson LH
Gynecol Oncol; 2010 Feb; 116(2):286-9. PubMed ID: 20109727
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
16. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
17. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.
Boruta DM; Gehrig PA; Fader AN; Olawaiye AB
Gynecol Oncol; 2009 Oct; 115(1):142-153. PubMed ID: 19592079
[TBL] [Abstract][Full Text] [Related]
18. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.
Winder AD; Maniar KP; Wei JJ; Liu D; Scholtens DM; Lurain JR; Schink JC; Buttin BM; Filiaci VL; Lankes HA; Ramirez NC; Park K; Singh M; Lieberman RW; Mannel RS; Powell MA; Backes FJ; Mathews CA; Pearl ML; Secord AA; Peace DJ; Mutch DG; Creasman WT; Kim JJ
Cancer; 2017 Apr; 123(7):1144-1155. PubMed ID: 27926776
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
20. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
